Trial Profile
Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs LY 3202626 (Primary) ; Itraconazole
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 25 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Dec 2015 Planned end date changed from 1 Jan 2016 to 1 Feb 2016, as reported by ClinicalTrials.gov.